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Abstract
Anxiety disorders, namely generalized anxiety disorder, panic disorder, and phobias, are common, 
etiologically complex conditions with a partially genetic basis. Despite differing on diagnostic 
definitions based upon clinical presentation, anxiety disorders likely represent various expressions 
of an underlying common diathesis of abnormal regulation of basic threat-response systems. We 
conducted genome-wide association analyses in nine samples of European ancestry from seven 
large, independent studies. To identify genetic variants contributing to genetic susceptibility shared 
across interview-generated DSM-based anxiety disorders, we applied two phenotypic approaches: 
(1) comparisons between categorical anxiety disorder cases and super-normal controls, and (2) 
quantitative phenotypic factor scores derived from a multivariate analysis combining information 
across the clinical phenotypes. We used logistic and linear regression, respectively, to analyze the 
association between these phenotypes and genome-wide single nucleotide polymorphisms. Meta-
analysis for each phenotype combined results across the nine samples for over 18 000 unrelated 
individuals. Each meta-analysis identified a different genome-wide significant region, with the 
following markers showing the strongest association: for case-control contrasts, rs1709393 located 
in an uncharacterized non-coding RNA locus on chromosomal band 3q12.3 (P=1.65×10−8); for 
factor scores, rs1067327 within CAMKMT encoding the calmodulin-lysine N-methyltransferase 
on chromosomal band 2p21 (P=2.86×10−9). Independent replication and further exploration of 
these findings are needed to more fully understand the role of these variants in risk and expression 
of anxiety disorders.
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Anxiety disorders (ADs), namely generalized anxiety disorder (GAD), panic disorder (PD), 
and phobias, are relatively common, often disabling conditions with lifetime prevalence of 
over 20% (Kessler et al, 2005). Family and twin studies suggest both genetic and 
environmental factors underlying their etiology, with moderate levels of familial aggregation 
(OR 3–6) and heritability (30–50%) (1). As with most complex genetic traits, many linkage 
and candidate gene association studies of ADs have been conducted, with little success in 
robustly identifying their susceptibility genes (2;3).
Genome-wide association studies (GWAS) have proven to be a successful method for the 
identification of common genetic variants that increase susceptibility to complex disease. 
Recently, GWAS of specific anxiety and related disorders such as PD (4;5), post-traumatic 
stress disorder (6–8), obsessive compulsive disorder (9;10), and phobias (11) have been 
published. However, these have been limited by small sample sizes and resulting low overall 
power to detect significant associations.
Despite differing on diagnostic definitions based upon clinical presentation, ADs likely 
represent various expressions of an underlying common diathesis of abnormal regulation of 
basic threat-response systems (12). ADs exhibit strong lifetime comorbidity with each other 
(13), with genetic epidemiologic studies pointing to shared genetic risk factors between 
them (14;15). Since clinical descriptions do not reflect underlying genetic architecture, 
traditional studies focused on individual ADs may not represent an effective study design for 
such phenotypes. A more informative approach would coordinate data from clusters of 
disorders with shared genetic risk factors (16). One such strategy is to model a latent anxiety 
liability factor indexing ADs with substantial genetic overlap. Also, for common disorders 
like ADs, disease states can be interpreted as extremes of continuous liability dimensions, as 
has been done for somatic illnesses like obesity and hypertension. Therefore, quantitative 
trait approaches, assuming a continuous liability distribution, can be used to construct 
informative latent psychiatric phenotypes (17). Analyzing AD phenotypes in a coordinated 
manner may represent a powerful approach for identifying susceptibility genes for ADs. 
This strategy has yielded some success, as demonstrated by prior reports from our group 
(18).
In the current study, we conducted genome-wide association analyses in nine large, 
independent samples. To identify genetic variants contributing to genetic susceptibility 
shared across the ADs, we applied two phenotypic approaches: (1) categorical case-control 
comparisons based upon having any AD diagnosis, and (2) quantitative phenotypic factor 
scores derived from a multivariate analysis combining information across the clinical 
phenotypes. We performed a meta-analysis for each phenotype across the nine samples for 
over 18 000 unrelated individuals using around 6.5 million imputed SNPs. This represents 
the largest genetic study to date of any of the ADs and the first of this magnitude to 
explicitly incorporate comorbidity structure directly into prediction of SNP effects.
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Materials and Methods
Overview
We conducted parallel GWAS in nine samples of European ancestry and combined the 
results via meta-analysis. We applied two phenotypic strategies aimed at capturing common 
(pleiotropic) genetic effects shared across the five core ADs: GAD, PD, social phobia, 
agoraphobia, and specific phobias. We conducted two types of analyses in each sample 
based upon complementary approaches to modeling the comorbidity and common genetic 
risk across the ADs: (1) case-control (CC) comparisons, in which cases were designated as 
having “any AD” versus supernormal controls, and (2) quantitative factor scores (FS) 
estimated for every subject in the sample using confirmatory factor analysis.
Samples
Nine samples containing AD phenotypes from seven independent studies participating in the 
Anxiety NeuroGenetics STudy (ANGST) Consortium were included in the meta-analysis. 
Standardized assessment instruments were used to generate DSM-based AD diagnoses, with 
some exceptions. The samples were genotyped on various SNP arrays according to their 
original study designs. Genotype calling, quality control (QC), imputation, and association 
analyses were performed at each site under similar standard protocols. SNP imputation was 
conducted within each sample using IMPUTE2 (19) or MACH (20) software utilizing the 
full 1000 Genomes Project reference data (March 2012, release v3). Genomic locations were 
based on NCBI build 37/UCSC hg 19 data. After imputation, SNPs with MAF<0.01, poor 
imputation quality <0.30, and Hardy-Weinberg equilibrium p-value <10−6 were removed. 
See Supplement for study descriptions and Supplemental Table S1 for details of genotyping 
and QC procedures. Table 1 summarizes basic statistics by cohort.
Genome-wide association analyses
To identify genetic variants contributing to genetic susceptibility shared across the ADs, we 
applied and compared two complementary phenotypic approaches: (1) categorical CC 
comparisons, and (2) quantitative phenotypic FS. For CC comparisons, AD cases were 
assigned to subjects meeting criteria for any lifetime AD (ANX=2) while control subjects 
were “super-normal”, i.e., having few or no clinical anxiety symptoms (ANX=0); those with 
subsyndromal ADs (ANX=1) were excluded from the CC analyses. For FS analyses, first 
exploratory factor analyses were conducted using Mplus (version 4) (39) separately in each 
sample, finding evidence for a single common factor model by scree plots. This was 
followed by confirmatory factor analyses that estimated a single FS for each subject from 
this common AD liability factor. (See Supplement for details of phenotype construction.) 
Association analyses were then performed in each study independently with imputed SNP 
dosages under an additive genetic model using logistic regression for CC phenotype and 
linear regression for quantitative FS phenotype. As covariates, we used sex and age at 
interview, as they were significant predictors of the phenotypes. Ancestry principal 
components were estimated for each sample and included on a sample-by-sample basis 
depending on their correlation with the outcome phenotypes. The quantile-quantile (Q-Q) 
plot was used to evaluate overall significance of the association test results and the genomic 
control factor λ.
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Meta-analysis of GWAS
We performed an inverse-variance weighted, fixed-effects meta-analysis with all GWAS 
samples using METAL (21) (nine samples using CC phenotypes and eight using FS 
phenotypes). For each SNP, a pooled effect size, standard error, and p-value were computed. 
SNPs with low MAF (<0.05) were excluded, resulting in a final meta-analytic data set of 
around 6.5M SNPs. Cochran’s Q statistics and corresponding I2 statistics were used as 
heterogeneity metrics. Cochran’s Q statistic was computed by summing the squared 
deviations of each study’s estimate by weighting each study’s contribution in the same 
manner as in the meta-analyses. I2 measured the amount of heterogeneity that is not due to 
chance.
Q-Q and Manhattan plots were examined, and False Discovery Rate (FDR) q-values were 
calculated based on the p-values from the meta-analyses. Q-values provide a balance 
between type I and Type II errors and can be interpreted as the probability that a marker 
identified as significant is a false discovery (22).
Cross-validation
In order to examine overall consistency of association between datasets, we employed a 
leave-one-out procedure for internal cross-validation. At each step, we meta-analyzed eight 
of the nine CC GWAS samples as the “training” set (seven of the eight samples were used 
for FS), the results of which were then tested in the respective remaining target sample 
(“testing” set). The top associated SNPs in the training set (Ptraining<1×10−5, pruned to 
r2<0.4 within a 500-kb window) were used to test the replicability (Ptesting<0.05) and 
consistency of the direction of their effects with the top associated SNPs identified in each 
testing set. One thousand random permutations of phenotype allocation to an individual’s 
genome-wide genotypes were performed in each training-testing set pair, totaling 9,000 and 
8,000 permutations in CC and FS, respectively. Across all sets, we compared the aggregate 
numbers of replicated SNPs and SNPs with the same direction of effect against the numbers 
expected by chance.
Gene-based tests
The SNP-based p-values derived from the meta-analyses were applied to gene-based 
association testing using KGG software (http://statgenpro.psychiatry.hku.hk/limx/kgg/) (23). 
No prioritization or preselection of genes was performed. Gene-based tests in KGG combine 
univariate association statistics to evaluate the cumulative evidence of association in a gene 
using extended Simes test (GATES) (24). SNPs were mapped onto 23 931 genes according 
to the gene coordinate information from NCBI, and SNPs within 10-kb of each gene were 
assigned to that gene. We considered genes with P<2×10−6 (=.05/23 931) as significant and 
those with q-value <0.1 as interesting (25).
Secondary Analyses
We conducted several secondary analyses, the details of which are described in the 
Supplement.
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1. SNP-based Heritability. Genomic-relatedness-matrix restricted maximum 
likelihood (GREML), as implemented in the software program GCTA 
(26), was conducted in our largest cohort (RS) to estimate the total amount 
of variance explained by all analyzed SNPs. This was supplemented by a 
similar procedure in the full meta-analytic sample using LD score 
regression (27).
2. Polygenic Risk Profile Analyses. Given the observed high comorbidity 
between ADs and other psychiatric syndromes, genomic profile risk scores 
(GPRS) (28) were estimated to test the additive joint effects of multiple 
variants between our AD GWAS data as target samples and summary data 
from Psychiatric Genomics Consortium phase 1 (PGC1) schizophrenia 
(SCZ), bipolar disorder (BIP), and MDD as discovery samples.
RESULTS
GWAS Meta-analysis
We performed an inverse-variance weighted, fixed-effects meta-analysis with all discovery 
GWAS data including approximately 6.5M common SNPs after applying post-imputation 
QC to each study. The genomic inflation factor λ ranged from 0.990 to 1.038 for all studies. 
The Q-Q plots of the meta-analyses for the CC and FS phenotypes are presented in Figure 1. 
Meta-analytic inflation factors were 1.03 and 1.02, suggesting little effect of population 
stratification. Manhattan plots are presented in Figure 2. Table 2 lists the LD-independent, 
genome-wide significant SNPs and associated regions. For the CC model, the strongest 
association was observed at rs1709393 located in an intron of an uncharacterized non-coding 
RNA locus LOC152225 on chromosome 3q12.3 (P=1.65×10−8; Q=0.027). Allelic 
frequencies were very similar across studies and ranged between 0.55 and 0.60. The most 
significant SNP in the FS model was rs1067327 on chromosome 2p21 within CAMKMT 
encoding the calmodulin-lysine N-methyltransferase (P=2.86×10−9; Q=0.0017) with LD 
extending into several adjacent genes. Allelic frequencies were consistent across studies, 
ranging from 0.32 to 0.36. Both of these SNPs were imputed with very high quality across 
studies (R2>0.93). As indicted in the forest plots (Supplementary Figure S1), no 
heterogeneity of effects was observed for either SNP. Figure 3 displays the regional SNP 
plots for these two genome-wide significant loci.
Given that the CC and FS phenotypic approaches provide conceptually different but 
otherwise complementary information, we estimated the overlap in their association signals. 
These phenotypes were highly correlated in the different cohorts (0.88–0.94). Overall rank-
based correlations between the CC and FS association effects were 0.61. The degree of 
correlation increased with decreasing p-value threshold, ranging from 0.275 to 0.899 
(Supplementary Table S3). The most significant SNPs all have the same direction of effect 
(top 1,000 SNPs in CC and top 1,500 SNPs in FS); indeed, among the approximately 30% of 
total SNPs with opposite sign, none had even suggestively significant association 
(P<1×10−5). However, among ~1.4M independent SNPS (pruned at r2=0.4), significantly 
more with P<10−5 were identified for the FS phenotype than for the CC phenotype: 42 
verses 18 (test p-value=0.0034).
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Cross-Validation
In the leave-one-out cross-validation analyses, the replication rate was significantly higher 
than expected by chance (Table 3). In CC, 18 of 173 tested SNPs across all leave-one out 
analyses replicated in the left out testing sets (permutation P=0.001) and the proportion of 
SNPs with the same direction of effect was 59.5% (sign test P=0.005). Of 315 tested SNPs 
in FS, 43 SNPs replicated (permutation P<0.001) and 77.8% had the same direction of effect 
(sign test P<0.001). Supplemental Figure S2 displays Manhattan plots of the training set 
meta-analyses conducted after leaving out each sample.
Gene-based tests
In the CC model, LOC152225 on 3q12.3 surpassed genome-wide significance 
(P=1.19×10−6; Q=0.028). In the FS model, three genes exceeded genome-wide significance: 
PREPL, CAMKMT, and SLC3A1 on chromosome 2 (Table 4). Supplementary Figure S3 
depicts the Manhattan plots for these gene-based analyses.
Secondary Analyses (see Supplement for details)
1. SNP-based heritability. This was estimated by GREML using GCTA in the 
Rotterdam sample as 0.106 (SE=0.06, P=0.05) for FS phenotype and 
0.138 (SE=0.18, P=0.2) for CC phenotype on the liability scale assuming 
10% AD population prevalence. Within the margin of error, these were 
consistent with LD score regression using summary statistics in the full 
meta-analysis sample, with SNP heritability estimated as 0.072 
(SE=0.028) for FS phenotype and 0.095 (SE =0.037) for CC phenotype.
2. Polygenic Risk Profile Analyses. GPRS from PGC-MDD explained a 
small but significant proportion of variance in CC ADs in QIMR (0.5%–
0.7%), while SCZ and BIP each explained a somewhat smaller proportion 
of this variance varying by sample. These results were supported by LD 
score regression performed in the meta-analysis sample, estimating 
significant genetic correlation between ADs and MDD (r=0.68) but not 
between ADs and BIP or SCZ.
DISCUSSION
We conducted the largest and most comprehensive genetic study of the primary anxiety 
disorders (ADs) to date. Specifically, we integrated phenotypic information on GAD, PD, 
agoraphobia, social phobia, and specific phobias and combined this with genome-wide SNP 
data from nine large samples totaling over 18 000 subjects. We conducted parallel GWAS in 
these samples and statistically combined the results via meta-analysis, with the aim of 
detecting common variants that play a role in shared AD susceptibility.
While only an approximate representation of the underlying complexity of AD genetic 
mechanisms, our integrated phenotypic approaches successfully identified novel genetic 
variants that significantly associate with these composite AD phenotypes. The results were 
generally the same whether analyzing individual SNPs or genes. In the CC model, we 
identified a novel genome-wide association within an uncharacterized non-coding RNA 
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locus LOC152225 on chromosome 3q12.3. We found no extant reports for this locus in 
PubMed or the NHGRI Catalogue of Published GWAS (www.genome.gov/gwastudies/). In 
the FS model, we detected genome-wide significant associations at SNPs in three genes 
within a large LD block on chromosome 2p21, each of which has reported expression in 
brain: (1) SLC3A1 encoding the large subunit of a heterodimeric dibasic /neutral amino acid 
transporter (solute carrier family 3 (amino acid transporter heavy chain), member 1); (2) 
PREPL encoding a putative prolyl endopeptidase belonging to the prolyl oligopeptidase 
family; and (3) CAMKMT encoding a calmodulin-lysine N-methyltransferase. This region 
is well-known for two contiguous gene-deletion syndromes, the hypotonia-cystinuria 
syndrome and the more severe 2p21 deletion syndrome (29). Deletion of SLC3A1 results in 
the autosomal-recessive form of cystinuria (30), while PREPL deletion causes hypotonia at 
birth, failure to thrive and growth hormone deficiency (31). The evolutionarily conserved 
class I protein methyltransferase encoded by CAMKMT acts in the formation of 
trimethyllysine in calmodulin which is involved in calcium-dependent signaling (32). 
Interestingly, GWAS of schizophrenia and bipolar disorder have highlighted other genes 
encoding proteins involved in calcium-dependent signaling (33). Although the most 
significant SNP, rs1067327, is located in an intron of CAMKMT , in silico analyses 
(Supplement) suggest rs698775 is the most likely functional candidate with a cis regulatory 
effect possibly specific to PREPL.
There is substantial phenotypic overlap between the CC and FS models used to capture the 
comorbidity and shared genetic risk among the ADs, and as expected, there was a high 
degree of concordance in the association signals genome-wide (Supplementary Table S3). 
The most significantly associated SNPs (p<.0.05) have very high correlation of association 
effects, suggesting they are tapping into strongly related AD risk factors. We note that, 
overall, the FS phenotype identified a larger number of associated SNPs than the CC model. 
This is likely due to several reasons: (1) this approach combines disorder information to 
capture individual differences on an underlying latent AD liability; (2) for high prevalence 
disorders, quantitative variables generally have greater power for genetic association than 
categorical variables (34;35); (3) the FS models generally involve larger sample sizes since 
they also include the subjects with subthreshold ADs (score=1); and (4) the FS model 
produces a phenotype that incorporates the observed relationship information (covariance) 
between the individual ADs. These findings support the use of quantitative phenotypic 
factors scores in future GWAS of comorbid psychiatric disorders assessed in the same 
individuals.
Several secondary analyses support our findings. First, we applied cross validation in the 
nine samples to examine the internal consistency of the results. We created sub-samples by 
iteratively removing the data of each of the individual samples and conducting meta-analysis 
with the remaining datasets. A highly significant proportion of the top results were 
consistently identified across these sub-analyses, suggesting the stability and validity of our 
findings. Next we estimated the genome-wide contribution via GREML and the 
complementary LD-score regression approach, producing generally consistent estimates of 
SNP heritability across samples included and methods applied. Similar to GWAS studies of 
many phenotypes (36), these estimates are substantially smaller than those predicted by twin 
studies of ADs. Finally, we tested the polygenic association between our results and those 
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from other psychiatric disorders using GRPS, finding significant correlation of genetic risk 
between ADs and MDD but not between ADs and BIP or SCZ. The former result is 
consistent with large epidemiologic studies that report correlated genetic risk between ADs 
and MDD (see (15) for review) as well as a prior overlap seen for depression and anxiety 
scales (37).
A strength of this study is that we applied phenotypic strategies aimed at detecting genetic 
variants that play a central but non-specific role in AD susceptibility. This is counter to the 
approach taken in most psychiatric genetic studies which generally apply case-control 
comparisons for specific clinical diagnoses, sometimes followed by adjunct cross-disorder 
analyses. However, it has long been recognized that clinical nosology poorly reflects 
etiological mechanisms, with both genetic and environmental risk factors showing non-
specific effects across disorders. ADs, despite their heterogeneous clinical presentations, 
likely represent various expressions of an underlying common diathesis of abnormal 
regulation of basic threat-response systems (12). Given the value of fear and anxiety for 
survival, there are likely sets of evolutionarily-conserved genes that regulate these basic 
biological responses. This is supported by twin studies that identify factors of common 
genetic risk across ADs in addition to disorder-specific genetic factors. With this in mind, 
we applied and compared two strategies for combining information across clinical 
phenotypes. The first is a simple CC approach, comparing cases defined as having “any AD” 
against supernormal controls. The second applied multivariate modeling of the covariation 
among the ADs using the common factor model to define a single continuous dimension of 
liability for which quantitative scores can be estimated for each subject. Our group has 
applied this approach in prior candidate gene association studies (18) and in a pilot GWAS 
in the MGS sample (38), but this is the first such application in a large GWAS meta-analysis. 
We note that this strategy is consistent with NIMH’s Research Domain Criteria (RDoC) 
initiative, which aims to serve as a framework for new approaches to research on mental 
disorders based on fundamental dimensions that cut across traditional disorder categories 
and more closely align with mechanisms that underlie psychopathology at various biological 
levels from genes to neural circuits (39). Also important to note is that ADs not only share 
genetic risk factors amongst themselves but also with other internalizing phenotypes like 
MDD (15), obsessive compulsive disorder (40), and personality traits like neuroticism and 
extroversion (41). It will be important for future studies to examine this broader pleiotropic 
spectrum either through cross-disorder GWAS as previously conducted for other psychiatric 
conditions (42) or by including these additional traits directly in the phenotypic construction 
with the ADs. It is possible that, by including AD cases with comorbid MDD, the genetic 
overlap between these conditions has influenced our results.
Several potential limitations of this study should be noted. First, although the total sample 
size far exceeds those from prior AD genetic studies, it is still relatively underpowered to 
detect common genetic variants of small effect expected for the genetic architecture of such 
complex phenotypes (37). Second, not all samples provided the same level of phenotypic 
coverage; in particular, some subjects in QIMR were missing diagnostic data for GAD or 
specific phobia. While this can produce bias, our forest plots, tests for heterogeneity, and 
internal validation analyses suggest that this likely did not bias our results. Third, consent 
agreements for some of the sites did not allow for sharing of subject data, so GWAS 
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analyses had to be conducted separately using a standardized procedure and combined via 
meta-analysis. While this has been shown to approximate the power obtained when using 
raw data via mega-analysis (38), we were limited in our ability to conduct additional post-
hoc analyses such as GPRS and GREML that require the use of raw GWAS data. 
Reassuringly, results obtained by applying LD score regression to summary statistics from 
the total meta-analysis sample were consistent with those using raw data from select 
individual samples. Fourth, the results apply only to subjects of European-ancestry and 
might not generalize to individuals of other genetic and cultural backgrounds. Finally, we 
combined all data available at the time of this study into a single meta-analysis rather than 
divide into discovery and replication samples. This was necessary due to the large sample 
sizes required to detect small effects of genes involved in complex traits like ADs. Internal 
cross-validation supported the robustness of our results but do not substitute for replication 
in well-powered, independent samples. At this time, we are unaware of other large data sets 
that could be used for replication of our results.
In summary, this study has identified several potentially novel susceptibility loci that 
increase shared risk across the primary ADs. Future studies are needed to (1) further confirm 
these findings via independent replication, (2) increase the total sample size to enhance 
power to detect additional loci, and (3) identify loci associated specifically with each 
particular AD not accounted for by the pleiotropic effects targeted in this study.
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Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This overall project was supported by NIH grant R01MH87646 to JMH. TO was supported by a research fellowship 
from the Japan Society for the Promotion of Science (no. 21-8373).
MGS
Samples and associated phenotype data for the MGS study were collected under the following grants: NIMH 
Schizophrenia Genetics Initiative U01s: MH046276 (CR Cloninger), MH46289 (C Kaufmann), and MH46318 (MT 
Tsuang); and MGS Part 1 (MGS1) and Part 2 (MGS2) R01s: MH67257 (NG Buccola), MH59588 (BJ Mowry), 
MH59571 (PV Gejman), MH59565(Robert Freedman), MH59587 (F Amin), MH60870 (WF Byerley), MH59566 
(DW Black), MH59586 (JM Silverman), MH61675 (DF Levinson), and MH60879 (CR Cloninger).
Rotterdam Study (RS)
This work is supported by the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands 
Genomics Initiative (NGI)/Netherlands Consortium for Healthy Ageing (NCHA) project No. 050-060-810. The 
work of Henning Tiemeier is supported by Vidi (grant 017.106.370). The Rotterdam Study is funded by Erasmus 
Medical Center, Rotterdam, the Netherlands Organization for the Health Research and Development (ZonMw), the 
Ministry of Education, Culture and Science, and the Ministry for Health, Welfare and Sports.
SHIP
SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded 
by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry 
of Cultural Affairs and the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide 
data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant 
from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania. This work 
was also funded by the German Research Foundation (DFG: GR 1912/5-1). The University of Greifswald is a 
member of the Caché Campus program of the InterSystems GmbH.
Otowa et al. Page 10
Mol Psychiatry. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
QIMR
The QIMR samples are made available through the generous and willing participation of twins and their families 
registered at the Australian Twin Registry and through grant funding awarded from many grant funding bodies 
including the Australian National Health and Medical Research Council (241944, 339462, 389927, 389875, 
389891, 389892, 389938, 442915, 442981, 496675, 496739, 552485, 552498, 613608), the FP-5 GenomEUtwin 
Project (QLG2-CT- 2002-01254), the US National Institutes of Health (NIH grants AA07535, AA10248, AA13320, 
AA13321, AA13326, AA14041, MH66206, DA12854, DA019951), and the Center for Inherited Disease Research, 
Baltimore. We thank Dixie Statham (sample collection); Leanne Wallace, Anthony Caracella and staff of the 
Molecular Epidemiology Laboratory (DNA processing); David Smyth, Harry Beeby, and Daniel Park (IT support). 
Statistical analyses were partly conducted at the Genetic Cluster Computer (http://www.geneticcluster.org), which is 
financially supported by the Netherlands Scientific Organization (NWO 480-05-003). EBM (1053639), SEM, DN, 
GWM, NRW (613602, 1078901) are supported by the National Health and Medical Research Council Fellowship 
Scheme.
PsyCoLaus
The CoLaus|PsyCoLaus study was and is supported by research grants from GlaxoSmithKline, the Faculty of 
Biology and Medicine of Lausanne, and the Swiss National Science Foundation (grants 3200B0–105993, 
3200B0-118308, 33CSCO-122661, 33CS30-139468 and 33CS30-148401).
TRAILS
Participating centers of TRAILS include various departments of the University Medical Center and University of 
Groningen, the Erasmus University Medical Center Rotterdam, the University of Utrecht, the Radboud Medical 
Center Nijmegen, and the Parnassia Bavo group, all in the Netherlands. TRAILS has been financially supported by 
various grants from the Netherlands Organization for Scientific Research NWO (Medical Research Council 
program grant GB-MW 940-38-011; ZonMW Brainpower grant 100-001-004; ZonMw Risk Behavior and 
Dependence grants 60-60600-97-118; ZonMw Culture and Health grant 261-98-710; Social Sciences Council 
medium-sized investment grants GB-MaGW 480-01-006 and GB-MaGW 480-07-001; Social Sciences Council 
project grants GB-MaGW 452-04-314 and GB-MaGW 452-06-004; NWO large-sized investment grant 
175.010.2003.005; NWO Longitudinal Survey and Panel Funding 481-08-013), the Dutch Ministry of Justice 
(WODC), the European Science Foundation (EuroSTRESS project FP-006), Biobanking and Biomolecular 
Resources Research Infrastructure BBMRI-NL (CP 32), the participating universities, and Accare Center for Child 
and Adolescent Psychiatry. Statistical analyses were carried out on the Genetic Cluster Computer (http://
www.geneticcluster.org), which is financially supported by the Netherlands Scientific Organization (NWO 
480-05-003) along with a supplement from the Dutch Brain Foundation.
NESDA/NTR
Funding was obtained from the Netherlands Organization for Scientific Research (Geestkracht program grant 
10-000-1002; 904-61-090, 985-10- 002, 904-61-193, 480-04-004, 400-05-717, 912-100-20; Spinozapremie 
56-464-14192); the Center for Medical Systems Biology (CSMB, NWO Genomics), Biobanking and Biomolecular 
Resources Research Infrastructure (BBMRI-NL), VU University’s Institutes for Health and Care Research (EMGO
+) and Neuroscience Campus Amsterdam, European Research Council (ERC, 230374),National Institutes of Health 
(NIH, R01D0042157-01A, MH081802, Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995). Part 
of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the 
Foundation for the National Institutes of Health. Computing was supported by BiG Grid, the Dutch e-Science Grid, 
which is financially supported by NWO.
Reference List
1. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of 
anxiety disorders. Am J Psychiatry. 2001 Oct; 158(10):1568–78. [PubMed: 11578982] 
2. Smoller JW, Block SR, Young MM. Genetics of anxiety disorders: the complex road from DSM to 
DNA. Depress Anxiety. 2009; 26(11):965–75. [PubMed: 19885930] 
3. Maron E, Hettema JM, Shlik J. Advances in molecular genetics of panic disorder. Mol Psychiatry. 
2010 Jul; 15(7):681–701. [PubMed: 20048750] 
4. Erhardt A, Czibere L, Roeske D, Lucae S, Unschuld PG, Ripke S, et al. TMEM132D, a new 
candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry. 2011 
Jun; 16(6):647–63. [PubMed: 20368705] 
Otowa et al. Page 11
Mol Psychiatry. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
5. Otowa T, Kawamura Y, Nishida N, Sugaya N, Koike A, Yoshida E, et al. Meta-analysis of genome-
wide association studies for panic disorder in the Japanese population. Transl Psychiatry. 2012; 
2:e186. [PubMed: 23149450] 
6. Logue MW, Baldwin C, Guffanti G, Melista E, Wolf EJ, Reardon AF, et al. A genome-wide 
association study of post-traumatic stress disorder identifies the retinoid-related orphan receptor 
alpha (RORA) gene as a significant risk locus. Mol Psychiatry. 2013 Aug; 18(8):937–42. [PubMed: 
22869035] 
7. Xie P, Kranzler HR, Yang C, Zhao H, Farrer LA, Gelernter J. Genome-wide association study 
identifies new susceptibility loci for posttraumatic stress disorder. Biol Psychiatry. 2013 Nov 1; 
74(9):656–63. [PubMed: 23726511] 
8. Guffanti G, Galea S, Yan L, Roberts AL, Solovieff N, Aiello AE, et al. Genome-wide association 
study implicates a novel RNA gene, the lincRNA AC068718.1, as a risk factor for post-traumatic 
stress disorder in women. Psychoneuroendocrinology. 2013 Dec; 38(12):3029–38. [PubMed: 
24080187] 
9. Stewart SE, Yu D, Scharf JM, Neale BM, Fagerness JA, Mathews CA, et al. Genome-wide 
association study of obsessive-compulsive disorder. Mol Psychiatry. 2013 Jul; 18(7):788–98. 
[PubMed: 22889921] 
10. Mattheisen M, Samuels JF, Wang Y, Greenberg BD, Fyer AJ, McCracken JT, et al. Genome-wide 
association study in obsessive-compulsive disorder: results from the OCGAS. Mol Psychiatry. 
2014 May 13.
11. Walter S, Glymour MM, Koenen K, Liang L, Tchetgen Tchetgen EJ, Cornelis M, et al. 
Performance of polygenic scores for predicting phobic anxiety. PLoS One. 2013; 8(11):e80326. 
[PubMed: 24278274] 
12. Craske MG, Rauch SL, Ursano R, Prenoveau J, Pine DS, Zinbarg RE. What is an anxiety disorder? 
Depress Anxiety. 2009; 26(12):1066–85. [PubMed: 19957279] 
13. Comorbidity of Mood and Anxiety Disorders. Washington, DC: American Psychiatric Press; 1990. 
14. Hettema JM, Prescott CA, Myers JM, Neale MC, Kendler KS. The structure of genetic and 
environmental risk factors for anxiety disorders in men and women. Arch Gen Psychiatry. 2005 
Feb; 62(2):182–9. [PubMed: 15699295] 
15. Middeldorp CM, Cath DC, van Dyck R, Boomsma D. The co-morbidity of anxiety and depression 
in the perspective of genetic epidemiology. A review of twin and family studies. Psychol Med. 
2005; 35(May):611–24. [PubMed: 15918338] 
16. Kendler KS, Prescott CA, Myers J, Neale MC. The structure of genetic and environmental risk 
factors for common psychiatric and substance use disorders in men and women. Arch Gen 
Psychiatry. 2003 Sep; 60(9):929–37. [PubMed: 12963675] 
17. Plomin R, Haworth CM, Davis OS. Common disorders are quantitative traits. Nat Rev Genet. 2009 
Dec; 10(12):872–8. [PubMed: 19859063] 
18. Hettema JM, An SS, Neale MC, Bukszar J, van den Oord EJ, Kendler KS, et al. Association 
between glutamic acid decarboxylase genes and anxiety disorders, major depression, and 
neuroticism. Molecular Psychiatry. 2006 May 23.
19. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype 
imputation in genome-wide association studies through pre-phasing. Nat Genet. 2012 Aug; 44(8):
955–9. [PubMed: 22820512] 
20. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to 
estimate haplotypes and unobserved genotypes. Genet Epidemiol. 2010 Dec; 34(8):816–34. 
[PubMed: 21058334] 
21. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association 
scans. Bioinformatics. 2010 Sep 1; 26(17):2190–1. [PubMed: 20616382] 
22. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S 
A. 2003 Aug 5; 100(16):9440–5. [PubMed: 12883005] 
23. Li MX, Sham PC, Cherny SS, Song YQ. A knowledge-based weighting framework to boost the 
power of genome-wide association studies. PLoS One. 2010; 5(12):e14480. [PubMed: 21217833] 
Otowa et al. Page 12
Mol Psychiatry. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
24. Li MX, Gui HS, Kwan JS, Sham PC. GATES: a rapid and powerful gene-based association test 
using extended Simes procedure. Am J Hum Genet. 2011 Mar 11; 88(3):283–93. [PubMed: 
21397060] 
25. van den Oord EJ, Sullivan PF. False discoveries and models for gene discovery. Trends Genet. 
2003 Oct; 19(10):537–42. [PubMed: 14550627] 
26. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait 
analysis. Am J Hum Genet. 2011 Jan 7; 88(1):76–82. [PubMed: 21167468] 
27. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD Score 
regression distinguishes confounding from polygenicity in genome-wide association studies. Nat 
Genet. 2015 Mar; 47(3):291–5. [PubMed: 25642630] 
28. Wray NR, Lee SH, Mehta D, Vinkhuyzen AA, Dudbridge F, Middeldorp CM. Research review: 
Polygenic methods and their application to psychiatric traits. J Child Psychol Psychiatry. 2014 
Oct; 55(10):1068–87. [PubMed: 25132410] 
29. Martens K, Jaeken J, Matthijs G, Creemers JW. Multi-system disorder syndromes associated with 
cystinuria type I. Curr Mol Med. 2008 Sep; 8(6):544–50. [PubMed: 18781961] 
30. Saravakos P, Kokkinou V, Giannatos E. Cystinuria: current diagnosis and management. Urology. 
2014 Apr; 83(4):693–9. [PubMed: 24246330] 
31. Martens K, Derua R, Meulemans S, Waelkens E, Jaeken J, Matthijs G, et al. PREPL: a putative 
novel oligopeptidase propelled into the limelight. Biol Chem. 2006 Jul; 387(7):879–83. [PubMed: 
16913837] 
32. Magnani R, Dirk LM, Trievel RC, Houtz RL. Calmodulin methyltransferase is an evolutionarily 
conserved enzyme that trimethylates Lys-115 in calmodulin. Nat Commun. 2010; 1:43. [PubMed: 
20975703] 
33. Neale BM, Sklar P. Genetic analysis of schizophrenia and bipolar disorder reveals polygenicity but 
also suggests new directions for molecular interrogation. Curr Opin Neurobiol. 2015 Feb.30C:
131–8. [PubMed: 25544106] 
34. Yang J, Wray NR, Visscher PM. Comparing apples and oranges: equating the power of case-
control and quantitative trait association studies. Genet Epidemiol. 2010 Apr; 34(3):254–7. 
[PubMed: 19918758] 
35. van der Sluis S, Posthuma D, Nivard MG, Verhage M, Dolan CV. Power in GWAS: lifting the curse 
of the clinical cut-off. Mol Psychiatry. 2013 Jan; 18(1):2–3. [PubMed: 22614290] 
36. Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J Hum 
Genet. 2012 Jan 13; 90(1):7–24. [PubMed: 22243964] 
37. Demirkan A, Penninx BW, Hek K, Wray NR, Amin N, Aulchenko YS, et al. Genetic risk profiles 
for depression and anxiety in adult and elderly cohorts. Mol Psychiatry. 2011 Jul; 16(7):773–83. 
[PubMed: 20567237] 
38. Otowa T, Maher BS, Aggen SH, McClay JL, van den Oord EJ, Hettema JM. Genome-wide and 
gene-based association studies of anxiety disorders in European and African American samples. 
PLoS One. 2014; 9(11):e112559. [PubMed: 25390645] 
39. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria 
(RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 
2010 Jul; 167(7):748–51. [PubMed: 20595427] 
40. Bienvenu OJ, Samuels JF, Wuyek LA, Liang KY, Wang Y, Grados MA, et al. Is obsessive-
compulsive disorder an anxiety disorder, and what, if any, are spectrum conditions? A family study 
perspective. Psychol Med. 2012 Jan; 42(1):1–13. [PubMed: 21733222] 
41. Bienvenu OJ, Hettema JM, Neale MC, Prescott CA, Kendler KS. Low extraversion and high 
neuroticism as indices of genetic and environmental risk for social phobia, agoraphobia, and 
animal phobia. Am J Psychiatry. 2007 Nov; 164(11):1714–21. [PubMed: 17974937] 
42. Cross-Disorder Group of the Psychiatric GWAS Consortium. Identification of risk loci with shared 
effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013 Apr 20; 
381(9875):1371–9. [PubMed: 23453885] 
43. Sanders AR, Levinson DF, Duan J, Dennis JM, Li R, Kendler KS, et al. The Internet-based MGS2 
control sample: self report of mental illness. Am J Psychiatry. 2010 Jul; 167(7):854–65. [PubMed: 
20516154] 
Otowa et al. Page 13
Mol Psychiatry. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
44. Preisig M, Waeber G, Vollenweider P, Bovet P, Rothen S, Vandeleur C, et al. The PsyCoLaus 
study: methodology and characteristics of the sample of a population-based survey on psychiatric 
disorders and their association with genetic and cardiovascular risk factors. BMC Psychiatry. 2009; 
9:9. [PubMed: 19292899] 
45. Hofman A, Breteler MM, van Duijn CM, Krestin GP, Pols HA, Stricker BH, et al. The Rotterdam 
Study: objectives and design update. Eur J Epidemiol. 2007; 22(11):819–29. [PubMed: 17955331] 
46. Schmidt CO, Watzke AB, Schulz A, Baumeister SE, Freyberger HJ, Grabe HJ. The lifetime 
prevalence of mental disorders in north-eastern Germany. What is the influence of earlier mental 
morbidity on survey participation and prevalence estimates? Results from the SHIP-study. 
Psychiatr Prax. 2013 May; 40(4):192–9. [PubMed: 23564355] 
47. Jardine R, Martin NG, Henderson AS. Genetic covariation between neuroticism and the symptoms 
of anxiety and depression. Genet Epidemiol. 1984; 1(2):89–107. [PubMed: 6544237] 
48. Oldehinkel AJ, Rosmalen JG, Buitelaar JK, Hoek HW, Ormel J, Raven D, et al. Cohort Profile 
Update: the TRacking Adolescents' Individual Lives Survey (TRAILS). Int J Epidemiol. 2015 Feb; 
44(1):76–76n. [PubMed: 25431468] 
49. Penninx BW, Beekman AT, Smit JH, Zitman FG, Nolen WA, Spinhoven P, et al. The Netherlands 
Study of Depression and Anxiety (NESDA): rationale, objectives and methods. Int J Methods 
Psychiatr Res. 2008; 17(3):121–40. [PubMed: 18763692] 
50. Boomsma DI, Vink JM, Van Beijsterveldt TC, de Geus EJ, Beem AL, Mulder EJ, et al. 
Netherlands Twin Register: a focus on longitudinal research. Twin Research. 2002 Oct; 5(5):401–
6. [PubMed: 12537867] 
51. Boomsma DI, de Geus EJ, Vink JM, Stubbe JH, Distel MA, Hottenga JJ, et al. Netherlands Twin 
Register: from twins to twin families. Twin Research and Human Genetics. 2006 Dec; 9(6):849–
57. [PubMed: 17254420] 
Otowa et al. Page 14
Mol Psychiatry. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Otowa et al. Page 15
Mol Psychiatry. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Quantile-quantile plots of meta-analysis results for (a) case-control and (b) factor score 
phenotypes. Observed association results of −log10P , after LD-pruning at r2 of 0.4, are 
plotted against the expected distribution under the null hypothesis of no association.
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Figure 2. 
Manhattan plots of meta-analysis results for (a) case-control and (b) factor score phenotypes. 
Red horizontal line indicates the genome-wide significant p-value 5×10−8; blue line 
indicates the suggestive p-value=1×10−5.
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Fig 3. 
Regional plots around most significant SNPs in (a) case-control and (b) factor score model.
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